

PRESS RELEASE

innate pharma

INNATE PHARMA ANNOUNCED 5.1 MILLION EUROS IN TURNOVER FOR THE FIRST NINE MONTHS OF 2007

Marseilles, November 6, 2007

Innate Pharma SA (the "Company"), a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, today announced a turnover of 5.1 million euros for the first nine months of 2007, compared with 4.5 million euros for the same period in 2006. The following table shows the turnover for the first nine months of 2006 and 2007, as well as the turnover for the third quarter of the same years:

In thousand of euros	Nine months ending September 30		Third quarter ending September 30	
	2006	2007	2006	2007
Revenue from collaboration and licensing agreements	4,492	5,060	2,583	1,458
Turnover	4,492	5,060	2,583	1,458

Turnover is constituted by revenue from collaboration and licensing agreements. Government funding for research costs is not included in the turnover but is part of the Company's operating revenue, released with first semester and full year results.


Innate Pharma's turnover comes mostly from the strategic partnership with Novo Nordisk A/S on the Company's NK platform (signed in March 2006). Turnover for the periods under review in 2007 is broken down as follows: (i) a portion of the lump sum payment received by Innate Pharma on signature of the agreement, (ii) annual research and development funding, and (iii) a payment related to a pre-clinical milestone successfully achieved with IPH 22XX in June 2007.

On signature of the partnership, Innate Pharma and Novo Nordisk A/S had indicated that they were expecting the first three years of the collaboration to generate around 25.0 million euros in revenue for Innate Pharma. Based on the latest developments on the NK platform, the Company is confident that it will achieve this goal. It now expects a minimum of 8.0 million euros in turnover for 2007, compared with 7.0 million euros announced previously.

Cash, cash equivalents and current financial instruments amounted to 52.0 million euros as at September 30, 2007. The Company expects to have around 50.0 million euros in cash, cash equivalents and current financial instruments as at December 31, 2007.

The Company invests its cash in money market mutual funds (valued daily) as well as in longer-term, capital-guaranteed available-for-sale financial assets based on money market instruments. Some of the latter also have a guarantee on minimum yield. Therefore, last summer's adverse credit market conditions will have no negative impact on the Company's cash, cash equivalents and current financial instruments.

Turnover for the first nine months of 2007 will be published in the French official bulletin BALO on November 6, 2007.



PRESS RELEASE

innate pharma

About Innate Pharma:

Founded in 1999 and funded by reference venture capitalists up to its IPO on Euronext in Paris in 2006, Innate Pharma S.A. (NYSE Euronext Paris: FR0010331421 – IPH) is a biopharmaceutical company developing first-in-class* drugs targeting innate immunity.

The pioneering work of Innate Pharma's scientific founders and research groups has led to the development of three drug candidate platforms (gamma delta T cells, NK cells and TLRs), each directly or indirectly validated in clinical oncology settings.

Besides cancer, Innate Pharma's drug candidates have development potential in the treatment of infectious diseases and chronic inflammation. The company's most advanced molecule is in Phase II clinical trials in cancer and viral infections.

With its strong scientific position in innate immunity pharmacology, its robust intellectual property portfolio and its R&D expertise, Innate Pharma intends to become a leading player in the rapidly growing immunotherapeutic market.

Based in Marseilles, France, Innate Pharma had 82 employees as of September 30, 2007.

Learn more about Innate Pharma at www.innate-pharma.com

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release, and the information contained herein, does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma

Stéphane Boissel, CFO

Tel. : +33 (0)4 96 19 05 58

stephane.boissel@innate-pharma.fr

Alize Public Relations

Caroline Carmagnol

Tel. : +33 (0)6 64 18 99 59

caroline@alizerp.com

* with new mechanisms of action.